Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review

References

• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease: how common is it? 2021; Available from: https://cks.nice.org.uk/topics/chronic-obstructive-pulmonary-disease/background-information/prevalence-incidence/. Accessed February 3, 2022.
   Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease (COPD); 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed February 3, 2022.
   Google Scholar
• Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(Suppl 2):5S–9S. doi:10.1378/chest.117.2_suppl.5S
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what? Clin Respir J. 2012;6(4):208–214. doi:10.1111/crj.12002
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report; 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed February 3, 2022.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report; 2022. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed March 20, 2023.
   Google Scholar
• Müllerová H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. doi:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J et al, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022); 2022. Available from: https://training.cochrane.org/handbook/current. Accessed February 3, 2022.
   Google Scholar
• PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses. PRISMA statement; 2021. Available from: http://prisma-statement.org/PRISMAStatement/PRISMAStatement.aspx. Accessed February 3, 2022.
   Google Scholar
• Hong QN, Pluye P, Fàbregues S, et al. Mixed Methods Appraisal Tool (MMAT) version 2018; 2018. Available from: http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf. Accessed February 3, 2022.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH search filters database; 2019. Available from: https://searchfilters.cadth.ca/. Accessed February 3, 2022.
   Google Scholar
• Gupta KK, Roy B, Chaudhary SC, et al. Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life. J Family Med Prim Care. 2018;7(1):53–57. doi:10.4103/jfmpc.jfmpc_18_17
   PubMedGoogle Scholar
• Chen CZ, Ou CY, Yu CH, Yang SC, Chang HY, Hsiue TR. Comparison of global initiative for chronic obstructive pulmonary disease 2013 classification and body mass index, airflow obstruction, dyspnea, and exacerbations index in predicting mortality and exacerbations in elderly adults with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2015;63(2):244–250. doi:10.1111/jgs.13258
   PubMed Web of Science ®Google Scholar
• Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int J Chron Obstruct Pulmon Dis. 2015;10:925–937. doi:10.2147/COPD.S82064
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respir Res. 2018;19(1):63. doi:10.1186/s12931-018-0767-2
   PubMedGoogle Scholar
• Chai CS, Mos SB, Ng DL, et al. Clinical phenotypes and health-related quality of life of COPD patients in a rural setting in Malaysia - a cross-sectional study. BMC Pulm Med. 2020;20(1):254. doi:10.1186/s12890-020-01295-4
   PubMed Web of Science ®Google Scholar
• Chai CS, Liam CK, Pang YK, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2019;14:565–573. doi:10.2147/COPD.S196109
   PubMed Web of Science ®Google Scholar
• Nurwidhiyasari D, Rachmi SF, Indracahyani A, Nuraini T. Relationship between severity and quality of life in chronic obstructive pulmonary disease patients at hospitals’ outpatient units in Jakarta. Enfermería Clínica. 2019;29(Suppl 2):159–165. doi:10.1016/j.enfcli.2019.04.024
   Google Scholar
• Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–1827. doi:10.2147/COPD.S87766
   PubMed Web of Science ®Google Scholar
• Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013;68(10):914–921. doi:10.1136/thoraxjnl-2013-203270
   PubMed Web of Science ®Google Scholar
• Song JH, Lee CH, Um SJ, et al. Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts. Int J Chron Obstruct Pulmon Dis. 2018;13:3473–3484. doi:10.2147/COPD.S177238
   PubMed Web of Science ®Google Scholar
• Li Y, Lim J, Stemkowski S, Kaila S, Renda A, Shaikh A. Initiation of triple therapy maintenance treatment among patients with COPD. Am J Manag Care. 2020;26(4):e106–e112 doi:10.37765/ajmc.2020.42837.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Kurihara Y, Takahashi K, et al. Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2020;20(1):318. doi:10.1186/s12890-020-01362-w
   PubMed Web of Science ®Google Scholar
• Lawrence PJ, Kolsum U, Gupta V, et al. Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients. BMC Pulm Med. 2017;17(1):42. doi:10.1186/s12890-017-0384-8
   PubMed Web of Science ®Google Scholar
• Kupryś-Lipińska I, Kuna P. Impact of chronic obstructive pulmonary disease (COPD) on patient’s life and his family. Pneumonol Alergol Pol. 2014;82(2):82–95. doi:10.5603/PiAP.2014.0014
   PubMedGoogle Scholar
• Rajnoveanu RM, Rajnoveanu AG, Ardelean AB, et al. Pulmonologists adherence to the chronic obstructive pulmonary disease GOLD guidelines: a goal to improve. Medicina (Kaunas). 2020;56(9):422. doi:10.3390/medicina56090422
   PubMed Web of Science ®Google Scholar
• Agarwal A, Batra S, Prasad R, Verma A, Jilani AQ, Kant S. A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population. Monaldi Arch Chest Dis. 2018;88(1):902. doi:10.4081/monaldi.2018.902
   PubMed Web of Science ®Google Scholar
• Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353–2361. doi:10.1001/jama.2013.5732
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Huang SY, Yang TM, et al. The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study. Int J Chron Obstruct Pulmon Dis. 2018;13:2949–2959. doi:10.2147/COPD.S176065
   PubMed Web of Science ®Google Scholar
• Faner R, Noell G, Badia JR, et al. Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respir Med. 2018;141:14–19. doi:10.1016/j.rmed.2018.06.015
   PubMed Web of Science ®Google Scholar
• Candemir I, Ergun P, Kaymaz D, Tasdemir F, Egesel N. The comparison of clinical variables in two classifications: GOLD 2017 combined assessment and spirometric stage of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2018;81(4):281–288. doi:10.4046/trd.2017.0114
   PubMed Web of Science ®Google Scholar
• Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J. What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis. 2018;13:3485–3492. doi:10.2147/COPD.S173664
   PubMed Web of Science ®Google Scholar
• Bikov A, Horváth A, Tomisa G, Bártfai L, Bártfai Z. Changes in the burden of comorbidities in patients with COPD and asthma-COPD overlap according to the GOLD 2017 recommendations. Lung. 2018;196(5):591–599. doi:10.1007/s00408-018-0141-7
   PubMed Web of Science ®Google Scholar
• Gedebjerg A, Szépligeti SK, Wackerhausen LH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204–212. doi:10.1016/S2213-2600(18)30002-X
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
   PubMed Web of Science ®Google Scholar
• Högman M, Sulku J, Ställberg B, et al. 2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group. Int J Chron Obstruct Pulmon Dis. 2017;2018(13):165–173 doi:10.2147/COPD.S151016.
   Google Scholar
• Jung YH, Lee DY, Kim DW, et al. Clinical significance of laryngopharyngeal reflux in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1343–1351. doi:10.2147/COPD.S84337
   PubMedGoogle Scholar
• Le LAK, Johannessen A, Hardie JA, et al. Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:1639–1655. doi:10.2147/COPD.S194019
   PubMed Web of Science ®Google Scholar
• Choi HS, Na JO, Lee JD, et al. Which GOLD B patients progress to GOLD D with the new classification? Int J Chron Obstruct Pulmon Dis. 2018;13:3233–3241. doi:10.2147/COPD.S177944
   PubMed Web of Science ®Google Scholar
• Cheng Y, Tu X, Pan L, et al. Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis. 2017;12:2069–2074. doi:10.2147/COPD.S140231
   PubMed Web of Science ®Google Scholar
• von Siemens SM, Jörres RA, Behr J, et al. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respir Res. 2019;20(1):30. doi:10.1186/s12931-019-0997-y
   PubMedGoogle Scholar
• Kamusheva M, Dimitrova M, van Boven JF, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. J Med Econ. 2017;20(5):503–509. doi:10.1080/13696998.2017.1279620
   PubMed Web of Science ®Google Scholar
• Cho J, Lee CH, Hwang YI, et al. Outcome of regular inhaled treatment in GOLD A chronic obstructive pulmonary disease patients. Respiration. 2019;98(4):312–320. doi:10.1159/000495756
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013;14(1):79. doi:10.1186/1465-9921-14-79
   PubMedGoogle Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
   PubMed Web of Science ®Google Scholar
• Han MZ, Hsiue TR, Tsai SH, Huang TH, Liao XM, Chen CZ. Validation of the GOLD 2017 and new 16 subgroups (1A–4D) classifications in predicting exacerbation and mortality in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:3425–3433. doi:10.2147/COPD.S179048
   PubMed Web of Science ®Google Scholar
• Echazarreta AL, Arias SJ, Del Olmo R, et al. Prevalence of COPD in 6 urban clusters in Argentina: the EPOC.AR study. Arch Bronconeumol (Engl Ed). 2018;54(5):260–269. doi:10.1016/j.arbres.2017.09.018
   PubMed Web of Science ®Google Scholar
• Yeung S, Chan P, Lai L, Chow K, Luk M, Chao D. Prevalence of different severities of chronic obstructive pulmonary disease in an out-patient clinic in Hong Kong. HK Pract. 2016;38:3–12.
   Google Scholar
• Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM. COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis. 2016;11:697–709. doi:10.2147/COPD.S100250
   PubMed Web of Science ®Google Scholar
• Plutinsky M, Brat K, Svoboda M, Zatloukal J, Popelkova P, Koblizek V. Prognostic accuracy of three COPD classification systems in relation to long-term mortality of COPD patients: a prospective multicenter study. Lung. 2019;197(2):173–179. doi:10.1007/s00408-019-00196-6
   PubMed Web of Science ®Google Scholar
• Ocheltree S, Male E, Zhao H, et al. Differences in GOLD 2017 treatment group assignments between the COPD assessment test and modified Medical Research Council Dyspnea Scale and their association with exacerbations: an analysis of the SPIROMICS cohort. Am J Respir Crit Care Med. 2019;199:A1113. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1113
   Web of Science ®Google Scholar
• García Castillo E, Alonso Pérez T, Ancochea J, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Res. 2020;6(4):00253–02020. doi:10.1183/23120541.00253-2020
   PubMedGoogle Scholar
• Cabrera López C, Casanova Macario C, Marín Trigo JM, et al. Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease reports. Impact on grouping and outcomes. Am J Respir Crit Care Med. 2018;197(4):463–469. doi:10.1164/rccm.201707-1363OC
   PubMed Web of Science ®Google Scholar
• Criner RN, Labaki WW, Regan EA, et al. Mortality and exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 versus 2017 in the COPDGene® cohort. Chronic Obstr Pulm Dis. 2019;6(1):64–73. doi:10.15326/jcopdf.6.1.2018.0130
   PubMed Web of Science ®Google Scholar
• Golpe R, Mengual-Macenlle N, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez-de-Llano LA. Prognostic indices and mortality prediction in COPD caused by biomass smoke exposure. Lung. 2015;193(4):497–503. doi:10.1007/s00408-015-9731-9
   PubMed Web of Science ®Google Scholar
• Oishi K, Hirano T, Hamada K, et al. Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:3901–3907. doi:10.2147/COPD.S181938
   PubMed Web of Science ®Google Scholar
• Ngo CQ, Thi Bui T, Vu GV, et al. Direct hospitalization cost of patients with acute exacerbation of chronic obstructive pulmonary disease in Vietnam. Int J Environ Res Public Health. 2018;16(1):88. doi:10.3390/ijerph16010088
   PubMed Web of Science ®Google Scholar
• Løkke A, Lange P, Lykkegaard J, et al. Economic burden of COPD by disease severity - a nationwide cohort study in Denmark. Value Health. 2020;23(Suppl 2):S720. doi:10.1016/j.jval.2020.08.1903
   Google Scholar
• Horner A, Burghuber OC, Hartl S, et al. Quality of life and limitations in daily life of stable COPD outpatients in a real-world setting in Austria - results from the CLARA project. Int J Chron Obstruct Pulmon Dis. 2020;15:1655–1663. doi:10.2147/COPD.S252033
   PubMed Web of Science ®Google Scholar
• Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007;29(10):2121–2133. doi:10.1016/j.clinthera.2007.10.006
   PubMed Web of Science ®Google Scholar
• Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS. Healthcare, medication utilization and outcomes of patients with COPD by GOLD classification in England. Int J Chron Obstruct Pulmon Dis. 2021;16:2591–2604. doi:10.2147/COPD.S318969
   PubMed Web of Science ®Google Scholar